Future Topics of Medical Writing

What has the next decade in store for medical writers and translators?

I still believe that personalised (or precision) medicine will be one of the dominant themes in medical content. But compared with a few years ago, the trend is now less theoretical and more operational: genomic services are expanding, targeted therapies are becoming routine in additional indications, and data-driven treatment decisions are moving from specialist centres into day-to-day care pathways.

For translators and medical writers, that means more than new vocabulary. It means more layered content: biomarker-driven eligibility criteria, nuanced risk language, mixed audience communication, and frequent updates as labels and guidelines evolve.

Personalised medicine is no longer niche

The underlying principle remains the same: clinical decisions are improved when we combine phenotype, molecular data, and context rather than applying one-size-fits-all pathways. What has changed is scale. National systems such as the NHS Genomic Medicine Service now frame genomics as routine infrastructure, not pilot activity.

This shift has immediate implications for content production. Writers are increasingly asked to explain complex concepts such as ctDNA, pharmacogenomics, and variant interpretation to mixed audiences: clinicians, regulators, and patients.

Immunotherapy in oncology: still moving fast

Immuno-oncology is no longer a “new frontier” in name, but it remains a fast-moving frontier in practice. Checkpoint strategies continue to move across indications and treatment lines. Recent FDA activity in hepatocellular carcinoma (first-line nivolumab plus ipilimumab in 2025) illustrates how quickly the evidence landscape can change.

For language professionals, this creates a constant translation challenge: mechanistic detail must be precise, while benefit-risk communication must remain clear across specialist and patient-facing outputs. The difference between “response”, “durability”, “progression”, and “overall survival benefit” is not stylistic; it is clinically material.

Rheumatology: more targeted choices, more complex messaging

Rheumatology has seen the same strategic pattern: broadened use of targeted biologics and pathway-specific agents, together with tighter treat-to-target framing. EULAR’s recommendations continue to evolve with this expanding option set, and real-world treatment sequencing is increasingly individualised.

In 2024, additional approvals around dual IL-17A/IL-17F inhibition in psoriatic arthritis and axial spondyloarthritis underlined that rheumatology language now regularly crosses domains: dermatology, gastroenterology, imaging, and long-term safety monitoring. Content teams therefore need sharper consistency around endpoints, domains of response, and safety caveats.

GLP-1 therapies and the Ozempic era

GLP-1 language has moved from specialist endocrinology into mainstream clinical and public discourse. Semaglutide-class medicines are now discussed across obesity medicine, cardiometabolic prevention, and increasingly broader policy and supply conversations. The FDA’s 2024 cardiovascular risk-reduction indication for Wegovy marked a major inflection point in how these therapies are framed.

At the same time, regulators have had to address safety communication and misuse. EMA’s recent updates include a very rare NAION signal and repeated warnings about falsified GLP-1 products sold online. For writers and translators, this means heightened responsibility: terminology must be exact, and risk communication must be balanced, transparent, and audience-appropriate.

What this means for medical writers and translators

• Content cycles are shorter: terminology and evidence shift quickly, so version control matters more than ever.
• Audience layering is now standard: one programme may require regulator-facing, clinician-facing, and patient-facing variants of the same core message.
• Precision language is expanding beyond oncology: rheumatology, cardiometabolic medicine, and hepatology now carry similar complexity burdens.
• Safety and supply communications are becoming more prominent: shortages, falsifications, and post-marketing signals demand clear, non-alarmist wording.

The next wave of work will not be shorter or simpler. It will be denser, more interdisciplinary, and more visible to non-specialist readers. That is exactly where specialist medical writing and translation become most valuable.